# Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)

> **NCT07662863** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 75 (estimated)

## Conditions studied

- Bladder Cancer
- Metastatic Urothelial Carcinoma
- Urothelial Carcinoma
- Peripheral Neuropathy

## Interventions

- **DRUG:** Sacituzumab Tirumotecan
- **DRUG:** MMAE-based ADC
- **DRUG:** Sacituzumab Tirumotecan (Observational Cohort)

## Key facts

- **NCT ID:** NCT07662863
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2028-12-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662863, "Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07662863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*